



Characteristics of Clinical Profiles in Psoriatic Arthritis Patients Initiating Ustekinumab by a Dermatologist or Rheumatologist

Pascal Richette^{1,*}, Samira Chaalal², Caren Constantin², Laure Cypiere² and Denis Jullien³

¹Department of Rheumatology, Lariboisière Hospital, Paris, France

²Department of Medical Affairs, Janssen-Cilag, Issy-les-Moulineaux, France

³Department of Dermatology, Centre Hospitalier Universitaire de Lyon (CHU), Lyon, France

© 2026 The Author(s). Published by Bentham Open.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: <https://creativecommons.org/licenses/by/4.0/legalcode>. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



CrossMark

*Address correspondence to this author at the Department of Rheumatology, Lariboisière Hospital, Paris, France-75010; Tel: 0148740250; Fax: 0149958631; E-mail: pascal.richette@aphp.fr

Published: October 07, 2026

Cite as: Richette P, Chaalal S, Constantin C, Cypiere L, Jullien D. Characteristics of Clinical Profiles in Psoriatic Arthritis Patients Initiating Ustekinumab by a Dermatologist or Rheumatologist. Open Rheumatol J, 2026; 20: e18743129415080. <http://dx.doi.org/10.2174/0118743129415080260216060406>



Send Orders for Reprints to reprints@benthamscience.net

Table S1. Disease assessment of patient population at baseline, week 16, and week 28.

Disease Type			Rheumatology Cohort (n=133)	Dermatology Cohort (n=70)	Total (N=203)
Painful joints	Baseline	n%	126 (94.7)	51 (72.9)	177 (87.2)
	Week 16	n%	120 (93.8)	54 (78.3)	174 (88.3)
	Week 28	n%	117 (92.9)	46 (70.8)	163 (85.3)
Swollen joints	Baseline	n%	128 (96.2)	48 (68.6)	176 (86.7)
	Week 16	n%	120 (93.8)	51 (73.9)	171 (86.8)
	Week 28	n%	116 (92.1)	46 (70.8)	162 (84.8)
Dactylitis	Baseline	n%	114 (85.7)	32 (45.7)	146 (71.9)
	Week 16	n%	109 (85.2)	37 (53.6)	146 (74.1)
	Week 28	n%	101 (80.2)	32 (49.2)	133 (69.6)
Enthesitis	Baseline	n%	91 (68.4)	19 (27.1)	110 (54.2)
	Week 16	n%	85 (66.4)	18 (26.1)	103 (52.3)
	Week 28	n%	86 (68.3)	25 (38.5)	111 (58.1)
Clinical features of PsO					
Nail lesions	Baseline	n%	103 (77.4)	49 (70.0)	152 (74.9)
	Week 16	n%	90 (70.3)	47 (68.1)	137 (69.5)
	Week 28	n%	90 (71.4)	42 (64.6)	132 (69.1)
BSA	Baseline	n%	99 (74.4)	52 (74.3)	151 (74.4)
	Week 16	n%	95 (74.2)	58 (84.1)	153 (77.7)
	Week 28	n%	91 (72.2)	47 (72.3)	138 (72.3)

Abbreviations: BSA: Body surface area; PsO: Psoriasis.




Fig. (S1). Study design.

DISCLAIMER: Please note that this article is currently in the 'Early view' stage and is not the final 'Version of Record'. While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although 'Early view' may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the 'Final Version of Record' becomes available the 'Early view' will be replaced by that.